10 Best Vaccine Stocks to Buy According to Hedge Funds

8. Moderna, Inc. (NASDAQ:MRNA)

Number of Hedge Fund Holders: 44

Moderna, Inc. (NASDAQ:MRNA) is a biotech company that develops vaccines based on messenger RNA (mRNA). While the company is experiencing weak sales and sluggish market adoption of its new products, it has strong fundamentals. Its elaborate pipeline of therapeutics in clinical trials lends it an optimistic outlook.

The company is focusing on maintaining its COVID-19 vaccination market share in 2025 and is advancing its late-stage candidate pipeline. Moderna, Inc. (NASDAQ:MRNA) is also anticipating FDA approval for an expanded indication of its RSV vaccine in the respiratory vaccine domain. It has also submitted a combination influenza-COVID-19 vaccine for approval, backed by positive phase 3 study data.

In addition, analysts are bullish on the company due to Moderna, Inc.’s (NASDAQ:MRNA) non-respiratory portfolio, which includes vaccines for norovirus and cytomegalovirus (CMV). mRNA-4157, under study in collaboration with Merck, also shows potential across various cancerous tumor types. This diverse pipeline reflects the company’s ability to divulge its mRNA technology into new categories, establishing itself as a more mature and diversified commercial-stage biotech company. The company ranks eighth on our list of the 10 best vaccine stocks to buy according to hedge funds.